Get started
NYKODE THERAPEUTICS ASANYKODE THERAPEUTICS ASANYKODE THERAPEUTICS ASA

NYKODE THERAPEUTICS ASA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NYKDO chart


Full chart

NYKDO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪976.37 M‬ NOK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.22 NOK
Net income (FY)
‪−371.59 M‬ NOK
Revenue (FY)
‪136.38 M‬ NOK
Shares float
‪156.23 M‬
Beta (1Y)
2.40

Employees


Employees (FY)
173
Change (1Y)
+18 +11.61%
Revenue / Employee (1Y)
‪788.32 K‬ NOK
Net income / Employee (1Y)
‪−2.15 M‬ NOK

About NYKODE THERAPEUTICS ASA


Sector
Health Technology
CEO
Michael Thyrring Engsig
Headquarters
Oslo
Website
nykode.com
Founded
2006
ISIN
NO0010714785
FIGI
BBG0189WJK97
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. It focuses on developing field of individualized cancer neoantigen vaccines by using the Vaccibody technology to generate therapeutics to treat cancer. The company was founded by Inger Sandlie and Agnete Brunsvik Fredriksen on November 22, 2006 and is headquartered in Oslo, Norway.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NYKDO news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NYKDO is 14.25 NOK — it has decreased by −6.86% in the past 24 hours. Watch NYKODE THERAPEUTICS ASA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange NYKODE THERAPEUTICS ASA stocks are traded under the ticker NYKDO.
We've gathered analysts' opinions on NYKODE THERAPEUTICS ASA future price: according to them, NYKDO price has a max estimate of 25.05 NOK and a min estimate of 2.50 NOK. Watch NYKDO chart and read a more detailed NYKODE THERAPEUTICS ASA stock forecast: see what analysts think of NYKODE THERAPEUTICS ASA and suggest that you do with its stocks.
NYKDO reached its all-time high on Aug 12, 2022 with the price of 39.00 NOK, and its all-time low was 13.05 NOK and was reached on Apr 17, 2024. View more price dynamics on NYKDO chart.
See other stocks reaching their highest and lowest prices.
NYKDO stock is 7.37% volatile and has beta coefficient of 2.40. Track NYKODE THERAPEUTICS ASA stock price on the chart and check out the list of the most volatile stocks — is NYKODE THERAPEUTICS ASA there?
Today NYKODE THERAPEUTICS ASA has the market capitalization of ‪943.07 M‬, it has increased by 7.76% over the last week.
Yes, you can track NYKODE THERAPEUTICS ASA financials in yearly and quarterly reports right on TradingView.
NYKODE THERAPEUTICS ASA is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
NYKDO earnings for the last quarter are −0.32 NOK per share, whereas the estimation was −0.47 NOK resulting in a 33.01% surprise. The estimated earnings for the next quarter are −0.54 NOK per share. See more details about NYKODE THERAPEUTICS ASA earnings.
NYKODE THERAPEUTICS ASA revenue for the last quarter amounts to ‪6.99 M‬ NOK, despite the estimated figure of ‪30.90 M‬ NOK. In the next quarter, revenue is expected to reach ‪18.85 M‬ NOK.
NYKDO net income for the last quarter is ‪−104.18 M‬ NOK, while the quarter before that showed ‪−79.47 M‬ NOK of net income which accounts for −31.09% change. Track more NYKODE THERAPEUTICS ASA financial stats to get the full picture.
No, NYKDO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 173.00 employees. See our rating of the largest employees — is NYKODE THERAPEUTICS ASA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NYKODE THERAPEUTICS ASA EBITDA is ‪−617.20 M‬ NOK, and current EBITDA margin is −423.64%. See more stats in NYKODE THERAPEUTICS ASA financial statements.
Like other stocks, NYKDO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NYKODE THERAPEUTICS ASA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NYKODE THERAPEUTICS ASA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NYKODE THERAPEUTICS ASA stock shows the sell signal. See more of NYKODE THERAPEUTICS ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.